Acute Kidney Injury Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments

Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Acute Kidney Injury pipeline constitutes 30+ key companies continuously working towards developing 30+ Acute Kidney Injury treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

Acute Kidney Injury Overview
Acute kidney injury (AKI), also known as acute renal failure (ARF), is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in the blood and makes it hard for the kidneys to keep the right balance of fluid in the person’s body. AKI can also affect other organs such as the brain, heart, and lungs. Acute kidney injury is common in patients who are in the hospital, in intensive care units, and especially in older adults

“Acute Kidney Injury Pipeline Insight, 2023“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Acute Kidney Injury Market.

The Acute Kidney Injury Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Acute Kidney Injury Pipeline Report:
• Companies across the globe are diligently working toward developing novel Acute Kidney Injury treatment therapies with a considerable amount of success over the years. Acute Kidney Injury Key players such as – Bessor Pharma, XORTX Therapeutics, RegeneRx Biopharmaceuticals, Sentien Biotechnologies, Pharming Group, Guard Therapeutics, Angion Biomedica, AMPharma Holding, and others, are developing therapies for the Acute Kidney Injury treatment
• Acute Kidney Injury Emerging therapies such as – BP 1002, Oxipurinol, Timbetasin, SBI 101, Conestat alfa, RMC 035, ANG-3777, Human recombinant alkaline phosphatase, and others are expected to have a significant impact on the Acute Kidney Injury market in the coming years.
• In July 2022, AM-Pharma announced new data indicating that ilofotase alfa protects against ischemia reperfusion induced acute kidney injury (AKI).

Route of Administration
Acute Kidney Injury pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Inhalation
• Inhalation/Intravenous/Oral
• Intranasal
• Intravenous
• Intravenous/ Subcutaneous
• Oral
• Oral/intranasal/subcutaneous
• Parenteral
• Subcutaneous

Molecule Type
Products have been categorized under various Molecule types, such as
• Antibody
• Antisense oligonucleotides
• Immunotherapy
• Monoclonal antibody
• Peptides
• Protein
• Recombinant protein
• Small molecule
• Stem Cell
• Vaccine

Acute Kidney Injury Pipeline Therapeutics Assessment
• Acute Kidney Injury Assessment by Product Type
• Acute Kidney Injury By Stage and Product Type
• Acute Kidney Injury Assessment by Route of Administration
• Acute Kidney Injury By Stage and Route of Administration
• Acute Kidney Injury Assessment by Molecule Type
• Acute Kidney Injury by Stage and Molecule Type

DelveInsight’s Acute Kidney Injury Report covers around 30+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Some of the key companies in the Chronic Hepatitis B Virus Therapeutics Market include:
Angion Biomedica., Vifor Pharma, Quark Pharmaceutical, Novartis, Astellas Pharma, MediBeacon, Pharming Technologies, Alloksys., and others

Emerging Acute Kidney Injury Drugs Under Different Phases of Clinical Development Include:
• BP 1002: Bessor Pharma
• Oxipurinol: XORTX Therapeutics
• Timbetasin: RegeneRx Biopharmaceuticals
• SBI 101: Sentien Biotechnologies
• Conestat alfa: Pharming Group
• RMC 035: Guard Therapeutics
• ANG-3777: Angion Biomedica
• Human recombinant alkaline phosphatase: AMPharma Holding

Get a Free Sample PDF Report to know more about Acute Kidney Injury Pipeline Therapeutic Assessment

Acute Kidney Injury Pipeline Analysis:
The Acute Kidney Injury pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Acute Kidney Injury with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Acute Kidney Injury Treatment.
• Acute Kidney Injury key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Acute Kidney Injury Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Acute Kidney Injury market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Further Acute Kidney Injury product details are provided in the report. Download the Acute Kidney Injury pipeline report to learn more about the emerging Acute Kidney Injury therapies

Acute Kidney Injury Pipeline Market Drivers
• Increasing prevalence of Acute Kidney Injury
• Growing awareness regarding the early prognosis of the injury

Acute Kidney Injury Pipeline Market Barriers
• Lack of effective therapeutic interventions for prevention or treatment of Acute Kidney Injury
• High cost associated with the Acute Kidney Injury treatment

Scope of Acute Kidney Injury Pipeline Drug Insight
• Coverage: Global
• Key Acute Kidney Injury Companies: Bessor Pharma, XORTX Therapeutics, RegeneRx Biopharmaceuticals, Sentien Biotechnologies, Pharming Group, Guard Therapeutics, Angion Biomedica, AMPharma Holding, and others
• Key Acute Kidney Injury Therapies: BP 1002, Oxipurinol, Timbetasin, SBI 101, Conestat alfa, RMC 035, ANG-3777, Human recombinant alkaline phosphatase, and others
• Acute Kidney Injury Therapeutic Assessment: Acute Kidney Injury current marketed and Acute Kidney Injury emerging therapies
• Acute Kidney Injury Market Dynamics: Acute Kidney Injury market drivers and Acute Kidney Injury market barriers

Request for Sample PDF Report for Acute Kidney Injury Pipeline Assessment and clinical trials

Table of Contents
1 Acute Kidney Injury Report Introduction
2 Acute Kidney Injury Executive Summary
3 Acute Kidney Injury Overview
4 Acute Kidney Injury- Analytical Perspective In-depth Commercial Assessment
5 Acute Kidney Injury Pipeline Therapeutics
6 Acute Kidney Injury Late Stage Products (Phase II/III)
7 Acute Kidney Injury Mid Stage Products (Phase II)
8 Acute Kidney Injury Early Stage Products (Phase I)
9 Acute Kidney Injury Preclinical Stage Products
10 Acute Kidney Injury Therapeutics Assessment
11 Acute Kidney Injury Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Acute Kidney Injury Key Companies
14 Acute Kidney Injury Key Products
15 Acute Kidney Injury Unmet Needs
16 Acute Kidney Injury Market Drivers and Barriers
17 Acute Kidney Injury Future Perspectives and Conclusion
18 Acute Kidney Injury Analyst Views
19 Appendix
20 About DelveInsight
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Download Sample PDF Report to know more about Acute Kidney Injury drugs and therapies

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
www.delveinsight.com/consulting